Navigation Links
Abraxis BioScience Presents Data from Pre-Clinical Study That,Provide Evidence for Chemotherapy-Induced Angiogenesis and,Rationale for Combining nab-Paclitaxel (Abraxane) with,Anti-Angiogenic Agents to Increase Tumor Response

l protein-bound particles for injectable suspension) (albumin-bound) in January 2005 for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within six months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. The most serious adverse events associated with ABRAXANE in the randomized metastatic breast cancer study for which FDA approval was based included neutropenia, anemia, infections, sensory neuropathy, nausea, vomiting, and myalgia/arthralgia. Other common adverse reactions included anemia, asthenia, diarrhea, ocular/visual disturbances, fluid retention, alopecia, hepatic dysfunction, mucositis, and renal dysfunction. For the full prescribing information for ABRAXANE(R), please visit www.abraxane.com.

ABRAXANE was developed by Abraxis BioScience, Inc. ABRAXANE is marketed in the United States under a co-promotion agreement between Abraxis BioScience, Inc. and AstraZeneca Pharmaceuticals LP.

About Abraxis BioScience, Inc.

Abraxis BioScience, Inc. is an integrated global biopharmaceutical company dedicated to meeting the needs of critically ill patients. The company develops, manufactures and markets one of the broadest portfolios of injectable products and leverages revolutionary technology such as its nab(TM) platform to discover and deliver breakthrough therapeutics that transform the treatment of cancer and other life-threatening diseases. The first FDA approved product to use this nab platform, ABRAXANE(R), was launched in 2005 for the treatment of metastatic breast cancer. Abraxis trades on The Nasdaq Global Market under the symbol ABBI. For more information about the company and its products, please visit www.abraxisbio.com.

FORWARD-LOOKING STATEMENT

The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securitie
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Abraxis BioScience Presents Results from Pre-Clinical Study That Demonstrates nab-Rapamycins Robust Antitumor Properties and Ability to Target Intracellular Sites Such as the mTOR Pathway
2. Abraxis BioScience Presents Pre-Clinical Findings That Support Role of SPARC Expression in Cancer and the Role of the Nanoparticle Albumin Bound (nab) Technology Platform in Targeting the Pathway
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
5. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
6. IR BioSciences Announces Promising Data from Study of Its Compound Homspera
7. Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data From Nerve Regeneration Program at American Society for Neural Therapy and Repair Meeting
8. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
9. ImmuneRegen BioSciences Announces Promising Data on Homspera Suggesting Potential as a Co-Therapeutic Agent
10. Study in Cell by Magen BioSciences Co-Founder David E. Fisher Identifies New Roles in Skin Cancer Prevention for Key Tumor Suppressor Protein
11. IR BioSciences Announces Data Demonstrating Radilex Stimulation of Stem Cells Results in Hematopoietic Recovery Following Lethal Irradiation
Post Your Comments:
(Date:7/30/2014)... PARIS , July 30, 2014  Regeneron ... (EURONEXT: SAN and NYSE: SNY ) today ... alirocumab in people with hypercholesterolemia met their primary efficacy ... low-density lipoprotein cholesterol (LDL-C) at 24 weeks compared to ... antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). ...
(Date:7/30/2014)... YORK , July 30, 2014 ACCESS ... for oncology supportive care, announced that its novel product ... in an article on OncLive.com titled, "Study Finds Mouth ... Cancers."  Dr. Steve Sonis , a leading expert ... seen in the oncology community for evidence-based strategies for ...
(Date:7/30/2014)... , July 30, 2014   Bluegrass ... focused on innovating lifesaving devices and methods for ... million in Series A financing, which was led ... from the deal will allow Bluegrass Vascular to ... Catheter System, enhance manufacturing capabilities, and proceed with ...
Breaking Medicine Technology:Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8Access Pharmaceuticals Featured On OncLive.com 2Access Pharmaceuticals Featured On OncLive.com 3Bluegrass Vascular Technologies Raises $4.5M Series A Financing Led By Targeted Technology Funds 2
... Dilon expands its portfolio of breast imaging solutions ... Mammography Information System technology by KLAS for three ... loyalty are the foundation of PenRad,s success. Together ... and an information management system that significantly improves ...
... Hurricane Irene came rushing up the East Coast as a ... United States, many states in the Northeast began to worry. The ... hurricanes. Coastal towns from New Jersey all the way up to ... City was one that took steps that had not been seen ...
Cached Medicine Technology:Dilon Diagnostics® Partners With PenRad® 2Dilon Diagnostics® Partners With PenRad® 3Hospitals Evacuated in Preparation for Hurricane Irene with Aid of Pulse Oximeter 2
(Date:7/30/2014)... July 30, 2014 Hamilton Facial ... of its new Carmel office on July 30th. After ... finally be moving to the state-of-the-art suite, located only ... innovative space will allow for one-on-one patient comfort, shorter ... experience. , Dr. Hamilton’s new office-suite will continue ...
(Date:7/30/2014)... DRE Medical — a leading medical ... of its Medical Trade Shows & Conventions Calendar ... and equipment vendors. , The calendar is a continually-updating ... United States and around the world. Hundreds of entries ... is always growing. , Information listed on each trade ...
(Date:7/30/2014)... The Technology Association of Georgia in collaboration with ... issued its final call for applications and nominations for ... until August 29th 2014 to be considered for this ... the Excalibur Judging Committee. Companies selected as semi-finalists will ... interviewing process. , The TAG Excalibur Awards recognize ...
(Date:7/30/2014)... LTC Consumer, an independent, free online service to help ... Instant Quote tool on its website, LTCconsumer.com , announced ... are free and unlimited. , The Instant Quote tool ... including age, gender, and state of residence – and delivers ... to enter any contact information to get started). There is ...
(Date:7/30/2014)... July 30, 2014 Children’s Hospital of ... Safety Day from 4 p.m. to 7 p.m. Wednesday, ... 7 Mile Road, Livonia, MI 48152). The event will ... helmets, children’s activities, music, snacks and local public safety ... the Children’s Hospital of Michigan Foundation. , The ...
Breaking Medicine News(10 mins):Health News:Hamilton Facial Plastic Surgery Opens New Carmel Office 2Health News:DRE Launches Online Interactive Medical Trade Show Calendar 2Health News:Last Call for TAG 2014 Excalibur Awards Nominations and Applications 2Health News:Last Call for TAG 2014 Excalibur Awards Nominations and Applications 3Health News:LTC Consumer Launches Online Tool for Getting Instant Long Term Care Insurance Estimates 2Health News:Kohl’s, Children’s Hospital of Michigan Foundation Host Safety Day with Detroit Red Wings Defenseman Danny DeKeyser, Bike Helmets, Family Activities and More 2Health News:Kohl’s, Children’s Hospital of Michigan Foundation Host Safety Day with Detroit Red Wings Defenseman Danny DeKeyser, Bike Helmets, Family Activities and More 3Health News:Kohl’s, Children’s Hospital of Michigan Foundation Host Safety Day with Detroit Red Wings Defenseman Danny DeKeyser, Bike Helmets, Family Activities and More 4
... -- About 14 percent of strokes happen while people are ... to the hospital in time for a potentially brain-saving treatment, ... for ischemic stroke must be given within a few hours ... stroke symptoms often can,t receive the treatment since we can,t ...
... new to adolescents, researchers and physicians at Nationwide Children,s ... that is raising some concern among medical professionals. Often ... form of self-injurious behavior that involves inserting foreign objects ... into muscle. A recent study, published in the June ...
... prevalence of overall cardiovascular risk in the Spanish working population ... (8% on men and 2% in women). This prevalence increases ... farming sector, followed by construction, industry and services. "In ... of cardiovascular risk, but only a minority of these people ...
... ROCHESTER, Minn. - Constipation is definitely not a glamorous ... and costs more than $1 billion annually to evaluate ... bloating, discomfort, and straining associated with constipation lead sufferers ... researchers recently had success in the clinical trial of ...
... By Steven Reinberg HealthDay Reporter , MONDAY, May ... associated with a lethal nervous system disease known as amyotrophic ... explain, however, that this does not mean people with long ... they are at higher risk for it. "We have ...
... of U.S. veterans ages 70 and older finds that the ... methods. However, for many less healthy veterans the burdens of ... we really need to target screening in older adults, so ... while those who won,t benefit aren,t exposed to unnecessary burdens," ...
Cached Medicine News:Health News:Research Suggests 1 in 7 Strokes Happens During Sleep 2Health News:A new study on self-injury behavior encourages quick and targeted intervention 2Health News:6 percent of Spanish workers have high cardiovascular risk 2Health News:Mayo Clinic researchers find new treatment for constipation 2Health News:Ring Finger Length Linked to ALS, Study Suggests 2Health News:Ring Finger Length Linked to ALS, Study Suggests 3Health News:Blood test for colon cancer screening beneficial for some seniors, but not for many others 2
... premium product for acne, XtremeClear, powered ... on a scalable multi-application platform. A ... acne, XtremeClear works fast, providing noticeable ... treatments. Uncompromising safety in each of ...
... SpaTouch was designed specifically to meet the varying ... is a simple to use, compact, dual application ... lucrative field of light based hair removal. SpaTouch ... is safe for use on nearly all face ...
... all of the benefits and functionality ... the additional feature of being able ... scanner for importing and storage of ... images. This additional feature allows for ...
Inquire...
Medicine Products: